Immunocore (NASDAQ:IMCR) Trading Up 6.1%

Immunocore Holdings plc (NASDAQ:IMCR – Get Rating) shares were up 6.1% during mid-day trading on Friday . The stock traded as high as $64.50 and last traded at $64.50. Approximately 2,122 shares traded hands during mid-day trading, a decline of 99% from the average daily volume of 411,323 shares. The stock had previously closed at $60.81.

Analyst Ratings Changes

Several equities analysts have issued reports on IMCR shares. The Goldman Sachs Group upgraded Immunocore from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $33.00 to $80.00 in a research report on Friday, December 16th. Morgan Stanley boosted their target price on Immunocore from $72.00 to $79.00 and gave the stock an “overweight” rating in a research report on Thursday, November 10th. HC Wainwright boosted their target price on Immunocore from $80.00 to $90.00 and gave the stock a “buy” rating in a research report on Monday, November 21st. Finally, Barclays began coverage on Immunocore in a research report on Wednesday, November 30th. They set an “overweight” rating and a $80.00 target price for the company. Nine research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $79.13.

Immunocore Stock Up 4.5 %

The business has a fifty day moving average of $59.05 and a 200 day moving average of $52.04. The firm has a market cap of $2.79 billion, a P/E ratio of -36.94 and a beta of 0.55. The company has a quick ratio of 5.21, a current ratio of 5.23 and a debt-to-equity ratio of 0.25.

Immunocore (NASDAQ:IMCR – Get Rating) last released its quarterly earnings data on Wednesday, November 9th. The company reported $0.14 EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.40. Immunocore had a negative return on equity of 29.53% and a negative net margin of 59.17%. The business had revenue of $48.52 million during the quarter, compared to the consensus estimate of $37.73 million. On average, equities research analysts predict that Immunocore Holdings plc will post -0.54 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Royal Bank of Canada acquired a new position in Immunocore in the first quarter valued at about $79,000. Tower Research Capital LLC TRC grew its stake in Immunocore by 1,003.5% in the third quarter. Tower Research Capital LLC TRC now owns 3,145 shares of the company’s stock valued at $148,000 after acquiring an additional 2,860 shares during the period. Quantbot Technologies LP acquired a new position in Immunocore in the third quarter valued at about $196,000. Pura Vida Investments LLC acquired a new position in Immunocore in the second quarter valued at about $239,000. Finally, Bank of America Corp DE boosted its position in shares of Immunocore by 92.0% during the first quarter. Bank of America Corp DE now owns 6,832 shares of the company’s stock worth $204,000 after buying an additional 3,274 shares during the period. 65.11% of the stock is owned by institutional investors and hedge funds.

Immunocore Company Profile

(Get Rating)

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers.